SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

Researchers used cryo-EM, glycoproteomics, and modeling to generate the atomic structure of a fully glycosylated and membrane ...

In December 2024, a rumor began spreading online that a team of researchers at Yale University had found the "spike protein" of the SARS-CoV-2 virus, which is responsible for the COVID-19 illness ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Researchers have discovered a virus that could enter human cells in a similar way to COVID-19. But they caution it's much more poorly adapted to humans.

Then, the antibody called CoV2-biRN7 can attach to the spike protein's receptor-binding domain, or RBD, thus preventing the protein from infecting healthy human cells. In an in-vitro test (i.e. in ...

The paper has not been peer-reviewed. Post-vaccination syndrome patients had lower levels of antibodies against the SARS-CoV-2 spike protein versus healthy controls, likely because they stopped ...